Skip to main content
. 2020 Apr 28;26(16):1888–1900. doi: 10.3748/wjg.v26.i16.1888

Figure 1.

Figure 1

First and second line therapies for advanced hepatocellular carcinoma. RECIST: Response Evaluation Criteria for Solid Tumors; ECOG: Eastern Cooperative Oncology Group; SOR: Sorafenib.